FDA Updates Atazanavir Oral Powder Label

"On September 24, 2015, FDA approved revisions to the Reyataz (atazanavir) oral powder label to include dosing recommendations for patients three months and older weighing at least 5 kg. This represents the addition of a new pediatric weight band. Previously the oral powder formulation was for patients three months and older weighing at least 10 kg.   "Reyataz oral powder must be taken with ritonavir and is not recommended for use in children who weigh less than 5 kg."   The updated labeling will be available at the FDA website.   More information is available: FDA: Press release AIDSinfo: Patient fact sheet on atazanavir